The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.
Monte Rosa Therapeutics, a US-based precision medicine developer exploiting Institute of Cancer Research work, has secured $95m in a series C round led by Avoro Capital Advisors.
GV, a corporate venturing unit for internet technology group Alphabet, and investment and financial services group Fidelity, also took part in the round, as did RTW Investments, funds and accounts managed by BlackRock and funds and accounts advised by T Rowe Price Associates.
The new investors were joined by existing backers…
